Skip to the page

Data / Drug companies / Janssen Biotech, Inc.

Janssen Biotech, Inc.: 37 products in the FDA NDC directory, labeler code 57894

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Janssen Biotech, Inc. (labeler code 57894) lists 37 products in the FDA National Drug Code Directory, covering 17 finished drugs by generic name. By type: 36 prescription drugs, 1 cellular therapies. Its main marketing category is biologics (BLA). The newest product started marketing on March 17, 2026.

The request: Watch Janssen Biotech, Inc. (FDA labeler code 57894): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
57894
Products in commercial distribution
37
Packages
62
Finished drugs by generic name
17
Prescription products
36
Over the counter products
0
Flagged as original packager
19 of 19 products that carry the flag
Started marketing in the last 12 months
5
Earliest marketing start
August 24, 1998
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Biologics (BLA)2978.4%
New drug applications (NDA)821.6%

Products by type

TypeProductsShare
Prescription drugs3697.3%
Cellular therapies12.7%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Ustekinumab62
Amivantamab and hyaluronidase-lpuj (human recombinant)41
Golimumab31
Guselkumab31
Lazertinib21
Daratumumab21
Abiraterone acetate222
Talquetamab-tgvs21
Niraparib tosylate monohydrate and abiraterone acetate21
Teclistamab-cqyv21
Nipocalimab-aahu21
Infliximab22
Gemcitabine intravesical11
Daratumumab and hyaluronidase-fihj (human recombinant)11
Ciltacabtagene autoleucel11
Icotrokinra11
Amivantamab-vmjw11

Dosage forms

Dosage formProductsShare
Injection1335.1%
Injection, solution616.2%
Tablet, film coated616.2%
Injection, solution, concentrate410.8%
Solution38.1%
Injection, powder, lyophilized, for solution25.4%
Tablet12.7%
System12.7%
Injection, suspension12.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Icotyde57894-201Tablet, film coatedNew drug applications (NDA)March 17, 2026
Rybrevant Faspro57894-522InjectionBiologics (BLA)February 13, 2026
Rybrevant Faspro57894-515InjectionBiologics (BLA)February 13, 2026
Rybrevant Faspro57894-514InjectionBiologics (BLA)December 19, 2025
Rybrevant Faspro57894-510InjectionBiologics (BLA)December 19, 2025
Inlexzo57894-225SystemNew drug applications (NDA)September 14, 2025
Imaavy57894-801Injection, solution, concentrateBiologics (BLA)April 29, 2025
Imaavy57894-800Injection, solution, concentrateBiologics (BLA)April 29, 2025
Ustekinumab57894-444SolutionBiologics (BLA)April 1, 2025
Ustekinumab57894-441Injection, solutionBiologics (BLA)April 1, 2025
Ustekinumab57894-440Injection, solutionBiologics (BLA)April 1, 2025
Tremfya57894-651InjectionBiologics (BLA)September 11, 2024
Tremfya57894-650InjectionBiologics (BLA)September 11, 2024
Lazcluze57894-240Tablet, film coatedNew drug applications (NDA)August 20, 2024
Lazcluze57894-080Tablet, film coatedNew drug applications (NDA)August 20, 2024
Akeega57894-100Tablet, film coatedNew drug applications (NDA)August 11, 2023
Akeega57894-050Tablet, film coatedNew drug applications (NDA)August 11, 2023
Talvey57894-470InjectionBiologics (BLA)August 9, 2023
Talvey57894-469InjectionBiologics (BLA)August 9, 2023
Tecvayli57894-450InjectionBiologics (BLA)October 25, 2022
Tecvayli57894-449InjectionBiologics (BLA)October 25, 2022
Carvykti57894-111Injection, suspensionBiologics (BLA)February 28, 2022
Darzalex IV57894-505Injection, solution, concentrateBiologics (BLA)October 15, 2021
Infliximab57894-160Injection, powder, lyophilized, for solutionBiologics (BLA)October 5, 2021
Rybrevant57894-501InjectionBiologics (BLA)May 21, 2021

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.